TITLE

Capecitabine Provides Low Toxicity Antitumor Chemotherapy During Perioperative Period Of Colectomy: Experimental Study In Rats

AUTHOR(S)
Konstantinidis, Harilaos D.; Pissanidou, Theano T.; Sioga, Antonia C.; Economou, Louise D.; Demertzidis, Charalampos G.; Pissanidis, Nikolaos G.
PUB. DATE
October 2007
SOURCE
Internet Journal of Oncology;2007, Vol. 4 Issue 2, p2
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Early induction of chemotherapy in patients operated for colorectal carcinomas, may cause a significant delay in wound healing and multiply the risk of septic complications. Capecitabine is a new fluoropyrimidine carbamate with antineoplastic activity, indicated for the therapy of colorectal cancer. The impact of capecitabine administration during the perioperative period after colectomy was studied. Methods: Rats, which underwent colectomy and hand sutured colonic anastomosis, were pretreated with capecitabine. Sixty Wistar rats where randomized in two groups of 30 rats each. In the study group capecitabine was administered at therapeutic dose, from 1 week prior the operation throughout the study. Control group received placebo. Rats were sacrificed in groups of 10 animals on the 3rd, 7th and 14th postoperative days, in both experimental and control groups. Results: All animals of the experimental group gained weight postoperatively. No negative impact on the healing of experimental animal's colonic anastomoses was reported. The median bursting pressure was found to be significantly higher and histological findings showed less necrotic effects in experimental animals sacrificed on the 3rd day, in comparison to controls. Conclusions: Administration of capecitabine during colectomy does not have a negative impact on the recovery of preoperatively treated animals, neither on the healing of colonic anastomoses.
ACCESSION #
27366805

 

Related Articles

  • Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Ichikawa, W.; Uetake, H.; Shirota, Y.; Yamada, H.; Takahashi, T.; Nihei, Z.; Sugihara, K.; Sasaki, Y.; Hirayama, R. // British Journal of Cancer;10/20/2003, Vol. 89 Issue 8, p1486 

    Activation of 5-fluorouracil into its nucleotides requires phosphorylation by three pathways involving orotate phosphoribosyl-transferase (OPRT), uridine phosphorylase (UP), or thymidine phosphorylase (TP). In this study, we investigated the association between gene expressions of these three...

  • Systemic Therapy for Colorectal Cancer. Meyerhardt, Jeffrey A.; Mayer, Robert J. // New England Journal of Medicine;2/3/2005, Vol. 352 Issue 5, p476 

    Presents a review article on systemic therapy for colorectal cancer. Last review of the available therapies and the need for an update; Staging and other prognostic indicators; Mechanism of action and dose scheduling of fluorouracil; Oral fluoropyrimidines; Adjuvant therapy with fluorouracil;...

  • Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer. Tol, Jolien; Koopman, Miriam; Cats, Annemieke; Rodenburg, Cees J.; Creemers, Geert J.M.; Schrama, Jolanda G.; Erdkamp, Frans L.G.; Vos, Allert H.; van Groeningen, Cees J.; Sinnige, Harm A.M.; Richel, Dirk J.; Voest, Emile E.; Dijkstra, Jeroen R.; Vink-B�rger, Marianne E.; Antonini, Ninja F.; Mol, Linda; van Krieken, Johan H.J.M.; Dalesio, Otilia; Punt, Cornelis J.A. // New England Journal of Medicine;2/5/2009, Vol. 360 Issue 6, p563 

    Background: Fluoropyrimidine-based chemotherapy plus the anti�vascular endothelial growth factor (VEGF) antibody bevacizumab is standard first-line treatment for metastatic colorectal cancer. We studied the effect of adding the anti�epidermal growth factor receptor (EGFR) antibody...

  • Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer. Ribic, Christine M.; Sargent, Daniel J.; Moore, Malcolm J.; Thibodeau, Stephen N.; French, Amy J.; Goldberg, Richard M.; Hamilton, Stanley R.; Laurent-Puig, Pierre; Gryfe, Robert; Shepherd, Lois E.; Tu, Dongsheng; Redston, Mark; Gallinger, Steven // New England Journal of Medicine;7/17/2003, Vol. 349 Issue 3, p247 

    Background: Colon cancers with high-frequency microsatellite instability have clinical and pathological features that distinguish them from microsatellite-stable tumors. We investigated the usefulness of microsatellite-instability status as a predictor of the benefit of adjuvant chemotherapy...

  • Capecitabine versus Bolus Fluorouracil plus Leucovorin (Folinic Acid) as Adjuvant Chemotherapy for Patients with Dukesʼ C Colon Cancer: Economic Evaluation in an Italian NHS Setting. Di Costanzo, Francesco; Ravasio, Roberto; Sobrero, Alberto; Bertetto, Oscar; Vinante, Orazio; Luppi, Gabriele; Labianca, Roberto; Amadori, Dino; Barone, Carlo; Carlo Merlano, Marco; Longo, Flavia; Mansueto, Giovanni; Antonuzzo, Lorenzo; Gasperoni, Silvia // Clinical Drug Investigation;2008, Vol. 28 Issue 10, p645 

    BACKGROUND AND OBJECTIVE: In the recent X-ACT (Xeloda in Adjuvant Colon cancer Therapy) trial, oral capecitabine (Xeloda) demonstrated superior efficacy and an improved safety profile compared with infused fluorouracil + leucovorin (folinic acid) [FU+LV] in patients with DukesÂ’ C colorectal...

  • Chronomodulated chemotherapy with oxaliplatin, 5-FU and sodium folinate in metastatic gastrointestinal cancer patients: analysis of non-hematological toxicity and patient characteristics in a pilot investigation. Farker, K.; Merkel, U.; Wedding, U.; Hippius, M.; Höffken, K.; Hoffmann, A. // International Journal of Clinical Pharmacology & Therapeutics;2006, Vol. 44 Issue 1, p31 

    Objective: Several clinical trials have demonstrated that oxaliplatin is a useful agent in combination with 5-fluorouracil (5-FU) and folinic acid (FA) for the treatment of patients with colorectal carcinoma. The aims of this pilot study were to evaluate non-hematological toxicity and patient...

  • Adjuvant 5-fluorouracil in the treatment of localised ocular surface squamous neoplasia. Adam K Rudkin // British Journal of Ophthalmology;Jul2011, Vol. 95 Issue 7, p947 

    AIM: To report the outcome of treatment of localised non-invasive ocular surface squamous neoplasia (OSSN) where topical 5-fluorouracil (5-FU 1%) is used as an adjuvant to surgical excision. METHODS: The study was a prospective non-comparative interventional case series. 55 cases of primary...

  • Capecitabine as Adjuvant Treatment for Stage III Colon Cancer. Twelves, Chris; Wong, Alfred; Nowacki, Marek P.; Abt, Markus; Burris, Howard; Carrato, Alfredo; Cassidy, Jim; Cervantes, Andrés; Fagerberg, Jan; Georgoulias, Vassilis; Husseini, Fares; Jodrell, Duncan; Koralewski, Piotr; Kröning, Hendrik; Maroun, Jean; Marschner, Norbert; McKendrick, Joseph; Pawlicki, Marek; Rosso, Riccardo; Schüller, Johannes // New England Journal of Medicine;6/30/2005, Vol. 352 Issue 26, p2696 

    Background: Intravenous bolus fluorouracil plus leucovorin is the standard adjuvant treatment for colon cancer. The oral fluoropyrimidine capecitabine is an established alternative to bolus fluorouracil plus leucovorin as first-line treatment for metastatic colorectal cancer. We evaluated...

  • Cytotoxic drugs for gastric and colorectal cancer. Cunningham, David // BMJ: British Medical Journal (International Edition);12/16/89, Vol. 299 Issue 6714, p1479 

    Focuses on the efficacy of cytotoxic drugs for gastric and colorectal cancer. Percentage of tumor regression observed in cytotoxic drug-treated patients; Adverse effects of cytotoxic drugs; Clinical trial on the usefulness of regional chemotherapy of colorectal cancer.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics